Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

NCT05014724 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05014724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Lead sponsor
UCB Biopharma SRL
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyneuropathy (cidp)